Lexeo Therapeutics (LXEO) Free Cash Flow (2022 - 2026)
Lexeo Therapeutics recorded quarterly Free Cash Flow of -$21.2 million in Q1 2026, down 5.48% quarter-over-quarter from -$20.1 million in Q4 2025, and up 2.47% year-over-year from -$20.7 million in Q1 2025.
Lexeo Therapeutics' Free Cash Flow history runs 5 years deep, the most recent figure standing at -$21.2 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 2.47% year-over-year to -$21.2 million; the TTM figure through Mar 2026 stood at -$98.3 million (down 11.34% YoY), while the FY2025 annual figure was -$99.0 million, down 21.22% from the prior year.
- Free Cash Flow came in at -$21.2 million for Q1 2026 at Lexeo Therapeutics, down from -$20.1 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$13.2 million in Q2 2023 to a low of -$29.8 million in Q3 2025.
- A 5-year average of -$19.9 million and a median of -$19.2 million in 2023 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow plunged 104.88% in 2024 and surged 30.27% in 2025, its largest moves.
- Lexeo Therapeutics' Free Cash Flow stood at -$16.8 million in 2022, then climbed by 16.59% to -$14.1 million in 2023, then slumped by 104.88% to -$28.8 million in 2024, then surged by 30.27% to -$20.1 million in 2025, then decreased by 5.48% to -$21.2 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$21.2 million, -$20.1 million, and -$29.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Lexeo Therapeutics | 392.12 Mn | 199.07 Mn | - | -21.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.18 Mn |
| Mar 31, 2026 | -21.18 Mn |
| Dec 31, 2025 | -20.08 Mn |
| Dec 31, 2025 | -20.08 Mn |
| Sep 30, 2025 | -29.84 Mn |
| Sep 30, 2025 | -29.84 Mn |
| Jun 30, 2025 | -27.22 Mn |
| Jun 30, 2025 | -27.22 Mn |
| Mar 31, 2025 | -21.72 Mn |
| Mar 31, 2025 | -21.72 Mn |
| Dec 31, 2024 | -28.79 Mn |
| Dec 31, 2024 | -28.79 Mn |
| Sep 30, 2024 | -17.81 Mn |
| Sep 30, 2024 | -17.81 Mn |
| Jun 30, 2024 | -19.98 Mn |
| Jun 30, 2024 | -19.98 Mn |
| Mar 31, 2024 | -15.05 Mn |
| Mar 31, 2024 | -15.05 Mn |
| Dec 31, 2023 | -14.05 Mn |
| Dec 31, 2023 | -14.05 Mn |
| Sep 30, 2023 | -13.94 Mn |
| Sep 30, 2023 | -13.94 Mn |
| Jun 30, 2023 | -13.23 Mn |
| Jun 30, 2023 | -13.23 Mn |
| Mar 31, 2023 | -18.39 Mn |
| Mar 31, 2023 | -18.39 Mn |
| Dec 31, 2022 | -16.85 Mn |
| Dec 31, 2022 | -16.85 Mn |